PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges

gurufocus.com · 2026-09-09

On September 09, 2026, Leerink initiated coverage of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) with a Market Perform rating and a price target of $10. The firm

Read the full story at gurufocus.com →